The primary objective of the study is to determine any effect on growth following use of a nasal spray treatment versus a placebo nasal spray in children with seasonal allergic rhinitis (SAR) and/or perennial allergic rhinitis (PAR).

Ages Eligible for Study:  6 Years   -   12 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion criteria:

• Pre-menarcheal female subjects (ages 6 to 11).
• Male subjects (ages 6 to 12)
• Tanner Stage 1
• History of SAR (Seasonal Allergic Rhinitis) or PAR (Perennial Allergic Rhinitis) of at least one year with either a current level of allergic rhinitis symptoms that warrants treatment and/or expected symptoms during a majority of the study period.
• Positive skin test to an appropriate seasonal or perennial allergen.

Exclusion criteria:

• History of abnormal growth or gross malnutrition.
• clinically significant laboratory abnormality.
• History of any condition that may have substantially affected growth.
• Historical or current evidence of clinically significant, uncontrolled disease of any body system.
• Any asthma other than mild, intermittent asthma controlled by short-acting, beta-agonists.
• Recent major surgery and/or trauma to the legs.
• History of adrenal insufficiency.
• Current or prior treatment with any medication that may have a potential for an ongoing effect on linear growth.
• Use of corticosteroids, by any route, within 4 weeks prior to Visit 1.
• Any nasal condition or deformity that would impair nasal breathing or deposition of medication.
• Physical impairment that would affect the subject's ability to participate in the study.